Neither hypertonic saline nor carbocisteine reduces the incidence of exacerbations in people with non-cystic-fibrosis bronchiectasis, according to a randomised trial.
For #ADHDAwarenessMonth, #MIMSPharma presents a round-up of recent and upcoming product launches, licence extensions and discontinuations; supply issues; and research findings for this condition.
Symbicort 100/6 Turbohaler (formoterol/budesonide) has become the first inhaler to receive MHRA approval for maintenance and reliever therapy (MART) in children aged 6–11 years.
Atenza XL, a modified-release preparation of methylphenidate, is now available for #ADHD prescribing in children aged ≥6 years and adults when remedial measures alone prove insufficient.
There is no evidence that taking paracetamol during pregnancy causes autism in children, according to the MHRA, NHS England, and the UK Teratology Information Service.
Transdermal HRT may provide some protection against ischaemic heart disease in women with type II diabetes, but oral HRT may increase cardiovascular risks, according to research presented at #EASD.
On #WorldAlzheimersDay 🌎, MIMS Pharma reports that, according to a real-world, people with dementia are often prescribed antipsychotics at higher doses than NICE recommends.
The 2024 BTS/NICE/SIGN asthma guidelines could lead to the UK no longer topping the league of poor outcomes for this condition, advanced nurse practitioner Bev Bostock has said in a new podcast.
